All PlansCoverageMedium impact
New policies
Blue Cross Blue Shield of Rhode Island·RI · Oncology, Hematology·Physician / Facility
Effective date
Feb 1, 2020
We identified it
Jun 19, 2026
Summary
BCBS Rhode Island has created a new medical policy for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers effective February 1, 2020. This specialized cancer treatment policy will impact coverage and billing for CAR-T cell therapy procedures.
Action Required
Immediately: Billing team must review the full CAR-T cell therapy policy text in the Provider section of bcbsri.com under Medical Policy heading to understand coverage criteria, prior authorization requirements, and billing procedures for CAR-T cell therapy. Oncology providers should be notified of new policy requirements for cancer patients requiring this specialized treatment.